GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » The Medicines Co (NAS:MDCO) » Definitions » Insider Ownership

The Medicines Co (The Medicines Co) Insider Ownership : 3.99 % (As of May. 04, 2024)


View and export this data going back to 2000. Start your Free Trial

What is The Medicines Co Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, The Medicines Co's insider ownership is 3.99%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, The Medicines Co's Institutional Ownership is 26.01%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, The Medicines Co's Float Percentage Of Total Shares Outstanding is 30.18%.


The Medicines Co Insider Ownership Historical Data

The historical data trend for The Medicines Co's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

The Medicines Co Insider Ownership Chart

The Medicines Co Historical Data

The historical data trend for The Medicines Co can be seen below:

2019-03-31 2019-04-30 2019-05-31 2019-06-30 2019-07-31 2019-08-31 2019-09-30 2019-10-31 2019-11-30 2019-12-31
Insider Ownership 3.55 3.55 3.58 3.31 3.30 3.31 3.31 3.29 3.28 3.99

The Medicines Co Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


The Medicines Co (The Medicines Co) Business Description

Traded in Other Exchanges
N/A
Address
8 Sylvan Way, Parsippany, NJ, USA, 07054
The Medicines Company is a pharmaceutical firm that provides products to the U.S. hospital market. The company's primary commercial product, Angiomax, is an anticoagulant drug used in conjunction with aspirin for patients undergoing angioplasty. Medicines recently commercialized a new drug, Cleviprex, which is designed to control blood pressure in intensive-care settings.
Executives
Alexander J Denner director C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Peter Wijngaard officer: Chief Development Officer 8 SYLVAN WAY, PARSIPPANY NJ 07054
Paris Panayiotopoulos director ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Geno J Germano director 5 GIRALDA FARMS, MADISON NJ 07940
Sarah J. Schlesinger director C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Christopher T Cox officer: EVP & Chief Corp. Dev. Officer CADWALADER, WICKERSHAM & TAFT LLP, ONE WORLD FINANCIAL CENTER, NEW YORK NY 10281
Fredric N Eshelman director, officer: Executive Chairman PPD INC, 929 NORTH FRONT STREET, WILMINGTON NC 28401
Armin M Kessler director
Robert J Hugin director C/O THE MEDICINES CO, 8 CAMPUS DR, PARSIPPANY NJ 07054
Hiroaki Shigeta director THE MEDICINES COMPANY, 8 SYLVAN WAY, PARSIPPANY NJ 07054
Stuart A Kingsley officer: President and COO 152 CHESTNUT STREET, WEST NEWTON MA 02465
Robert G. Savage director C/O EPICEPT CORPORATION, 777 OLD SAW MILL ROAD, TARRYTOWN NY 10591
Glenn Sblendorio director, officer: President & CFO 3 TIMES SQAURE, 12TH FLOOR, NEW YORK NY 10036
James E Flynn 10 percent owner, other: Possible Members of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Management Company, L.p. (series C) 10 percent owner, other: Possible Members of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010